Phase II trial of idarubicin, fludarabine, Ara-C, and filgrastim filgrastim (G-CSF) (Ida-FLAG) for treatment of poor prognosis acute myeloid leukemia (AML).

被引：0
|
作者：
Wickramanayake, PD [1 ]
Steinmetz, HT [1 ]
Katay, I [1 ]
Glasmacher, A [1 ]
Staib, P [1 ]
Diehl, V [1 ]
机构：
[1] UNIV HOSP KOLN,DEPT INTERNAL MED 1,COLOGNE,GERMANY
来源：
BLOOD | 1995年 / 86卷 / 10期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：3009 / 3009
页数：1
相关论文
共 50 条
  • [41] Fludarabine, Cytarabine, G-CSF and Gemtuzumab Ozogamicin (FLAG-GO) Regimen Results in Better Molecular Response and Relapse-Free Survival in Core Binding Factor Acute Myeloid Leukemia Than FLAG and Idarubicin (FLAG-Ida)
    Borthakur, Gautam M.
    Cortes, Jorge E.
    Ravandi, Farhad
    Garcia-Manero, Guillermo
    Kadia, Tapan M.
    Jabbour, Elias
    Patel, Keyur
    Issa, Ghayas C.
    Daver, Naval G.
    Ohanian, Maro N.
    Brandt, Mark
    Kantarjian, Hagop M.
    BLOOD, 2019, 134
  • [42] Fludarabine, Cytarabine, G-CSF and Gemtuzumab Ozogamicin (FLAG-GO) Regimen Results in Better Molecular Response and Relapse-Free Survival in Core Binding Factor Acute Myeloid Leukemia Than FLAG and Idarubicin (FLAG-Ida)
    Borthakur, Gautam M.
    Cortes, Jorge E.
    Ravandi, Farhad
    Garcia-Manero, Guillermo
    Kadia, Tapan M.
    Jabbour, Elias
    Patel, Keyur
    Issa, Ghayas C.
    Daver, Naval G.
    Ohanian, Maro N.
    Brandt, Mark
    Kantarjian, Hagop M.
    BLOOD, 2019, 134
  • [43] Phase 2 Study of FLAGM (Fludarabine plus High-Dose Ara-C plus G-CSF plus Mitoxantrone) for Relapsed or Refractory Acute Myeloid Leukemia (AML): A Report From the Japan Adult Leukemia Study Group (JALSG).
    Miyawaki, Shuichi
    Hatsumi, Naoko
    Yamauchi, Takahiro
    Tsuboi, Kousuke
    Fujieda, Atsushi
    Takeshita, Akihiro
    Komatsu, Norio
    Usui, Noriko
    Arai, Yukihiro
    Ishida, Fumihiro
    Morii, Takeshi
    Kano, Yasuhiko
    Ogura, Michinori
    Doki, Noriko
    Ohnishi, Kazunori
    Naoe, Tomoki
    Ohno, Ryuzo
    BLOOD, 2009, 114 (22) : 437 - 438
  • [44] A combination of idarubicin, fludarabine, Ara-C and G-CSF induction with or without consolidation using busulfan and cytoxan (BU/CY) plus peripheral blood stem cell transplantation in patients with poor prognosis myelodysplastic syndrome (MDS) and acute myelogenous leukemia.
    Besa, EC
    Rousch, R
    Rovito, M
    BLOOD, 1997, 90 (10) : 4029 - 4029
  • [45] A phase I–II study of plerixafor in combination with fludarabine, idarubicin, cytarabine, and G-CSF (PLERIFLAG regimen) for the treatment of patients with the first early-relapsed or refractory acute myeloid leukemia
    David Martínez-Cuadrón
    Blanca Boluda
    Pilar Martínez
    Juan Bergua
    Rebeca Rodríguez-Veiga
    Jordi Esteve
    Susana Vives
    Josefina Serrano
    Belen Vidriales
    Olga Salamero
    Lourdes Cordón
    Amparo Sempere
    Ana Jiménez-Ubieto
    Julio Prieto-Delgado
    Marina Díaz-Beyá
    Ana Garrido
    Celina Benavente
    José Antonio Pérez-Simón
    Federico Moscardó
    Miguel A. Sanz
    Pau Montesinos
    Annals of Hematology, 2018, 97 : 763 - 772
  • [46] Clofarabine combinations in acute myeloid leukemia (AML) salvage: A dose-finding phase I study of clofarabine plus idarubicin and clofarabine/idarubicin plus cytarabine (ara-C)
    Faderl, S
    Ferrajoli, A
    Wierda, W
    Ravandi, F
    Estrov, Z
    Verstovsek, S
    Thomas, DA
    Garcia-Manero, G
    Kwari, M
    Kantarjian, HM
    BLOOD, 2005, 106 (11) : 786A - 786A
  • [47] A phase I-II study of plerixafor in combination with fludarabine, idarubicin, cytarabine, and G-CSF (PLERIFLAG regimen) for the treatment of patients with the first early-relapsed or refractory acute myeloid leukemia
    Martinez-Cuadron, David
    Boluda, Blanca
    Martinez, Pilar
    Bergua, Juan
    Rodriguez-Veiga, Rebeca
    Esteve, Jordi
    Vives, Susana
    Serrano, Josefina
    Vidriales, Belen
    Salamero, Olga
    Cordon, Lourdes
    Sempere, Amparo
    Jimenez-Ubieto, Ana
    Prieto-Delgado, Julio
    Diaz-Beya, Marina
    Garrido, Ana
    Benavente, Celina
    Antonio Perez-Simon, Jose
    Moscardo, Federico
    Sanz, Miguel A.
    Montesinos, Pau
    ANNALS OF HEMATOLOGY, 2018, 97 (05) : 763 - 772
  • [48] Correction to: A phase I–II study of plerixafor in combination with fludarabine, idarubicin, cytarabine, and G-CSF (PLERIFLAG regimen) for the treatment of patients with the first early-relapsed or refractory acute myeloid leukemia
    David Martínez-Cuadrón
    Blanca Boluda
    Pilar Martínez
    Juan Bergua
    Rebeca Rodríguez-Veiga
    Jordi Esteve
    Susana Vives
    Josefina Serrano
    Belen Vidriales
    Olga Salamero
    Lourdes Cordón
    Amparo Sempere
    Ana Jiménez-Ubieto
    Julio Prieto-Delgado
    Marina Díaz-Beyá
    Ana Garrido
    Celina Benavente
    José Antonio Pérez-Simón
    Federico Moscardó
    Miguel A. Sanz
    Pau Montesinos
    Annals of Hematology, 2018, 97 : 923 - 923
  • [49] Final analysis of a randomized study on the value of fludarabine in addition to ARA-C and G-CSF in the treatment of patients with high risk myelodysplastic syndromes and elderly AML.
    Ossenkoppele, G
    Graveland, W
    Sonneveld, P
    Daenen, S
    Biesma, D
    Verdonck, L
    Schaafsma, M
    Westveer, P
    Peters, G
    Noordhuis, P
    Muus, P
    Selleslag, D
    van der Holt, B
    Delforge, M
    Lowenberg, B
    Verhoef, G
    BLOOD, 2002, 100 (11) : 792A - 793A
  • [50] Cladribine (2-CDA) in combination with Ara-C. Etoposide and G-CSF is effective in secondary or relapsed acute myeloid leukemia (AML).
    Krieger, O
    Kasparu, H
    Girschikofsky, M
    Lutz, D
    BLOOD, 1996, 88 (10) : 3422 - 3422
12345